---
document_datetime: 2025-11-11 11:47:41
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uzprovo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: uzprovo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4044284
conversion_datetime: 2025-12-25 09:48:45.470944
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Uzpruvo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                    |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 11/11/2025                          |                                             | SmPC                             | To extend the shelf-life of Uzpruvo 130 mg |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308833                     | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                        | concentrate for solution for infusion (EU/1/23/1784/005), in accordance with the approved stability protocol, from 18 months to 24 months when stored at 2°C - 8°C, inclusive of 7 days of storage at room temperature up to 30°C.                                                                                                       |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000269651 | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/09/2025 | N/A |                        |                                                                                                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000268254 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003, and sections 4.8 and 5.1 of the SmPC to include patient exposure numbers based on results from study CNTO1275UCO3001, following approval of the same change for the reference product Stelara. Additionally, the MAH took the opportunity to update the | 16/05/2025 |     | SmPC, Labelling and PL | To update sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003, and sections 4.8 and 5.1 of the SmPC to include patient exposure numbers based on results from study CNTO1275UCO3001, following approval of the same change for the reference product Stelara. |

<div style=\"page-break-after: always\"></div>

|                                       | contact details for ET and LV in the list of local representatives and to align the wording for Figure 2 in the instructions for administration for the 45 mg vial presentation with the wording of the 45 mg pre-filled syringe. Furthermore, the MAH took the opportunity to make minor editorial amendments in the DA, ET, FI and PT product information for alignment with the QRD template and to correct the way one excipient is presented to align with other approved strengths.   |            |     |      |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000261203 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                     | 22/04/2025 |     | SmPC |
| Variation type IB / EMA/VR/0000255909 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting                                                                                                                                           | 18/03/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                          | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                            |            |     |    |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IA_IN / EMA/VR/0000255737 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 11/03/2025 |     | PL |
| Variation type IB / EMA/VR/0000246116    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Minor change in the manufacturing process of a sterile finished product after the primary packaging step - Accepted                                                                                                                      | 18/02/2025 | N/A |    |